Merck Constructs Manufacturing Facility for HPAPI and ADC Compounds

Published 10-26-2020
  • Merck - HPAPI & ADC Production Facility
  • Merck - HPAPI & ADC Production Facility

    Courtesy of Jacobs Engineering.

Merck is constructing a $69 million facility for the production of high-potency active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) compounds. Representing an expansion of the company's existing campus near Madison, the 70,000-sf structure will feature containment environments specifically designed for the manufacture of substances with single-digit nanogram occupational exposure limits. The building will allow the large-scale production of increasingly potent compounds for the creation of innovative cancer therapeutics. Jacobs Engineering is the design consultant for the project, which is slated for completion in mid-2022.

Related Organizations
Jacobs Engineering
Design Consultant